Soligenix Inc. Unveils Corporate Presentation Focused on Advancements in Rare Disease Treatment and Robust Pipeline

Reuters

2025/08/22

Soligenix Inc. Unveils Corporate Presentation Focused on Advancements in Rare Disease Treatment and Robust Pipeline

Soligenix, Inc., a late-stage biopharmaceutical company, has released a corporate presentation detailing their focus on developing and commercializing products for the treatment of rare diseases with unmet medical needs. The company operates in two main segments: Specialized BioTherapeutics, which targets orphan diseases and unmet medical needs in oncology and inflammation, and Public Health Solutions, which develops vaccines and therapeutics for military and civilian applications, including responses to ricin exposure, emerging infectious diseases, and viral diseases like Ebola, Marburg, and COVID-19. Soligenix highlights a robust pipeline with products in various stages of clinical trials, including promising candidates for conditions such as psoriasis and Behçet's disease. The presentation underlines collaborations with biotech firms, academia, and government agencies, along with non-dilutive government funding supporting vaccine development. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief on August 22, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2561477461"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2561477461\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2561477461?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-22 21:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561477461","market":"nz","top_or_hot":-1,"title":"Soligenix Inc. Unveils Corporate Presentation Focused on Advancements in Rare Disease Treatment and Robust Pipeline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Soligenix Inc. Unveils Corporate Presentation Focused on Advancements in Rare Disease Treatment and Robust Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SNGX\">Soligenix, Inc.</a>, a late-stage biopharmaceutical company, has released a corporate presentation detailing their focus on developing and commercializing products for the treatment of rare diseases with unmet medical needs. The company operates in two main segments: Specialized BioTherapeutics, which targets orphan diseases and unmet medical needs in oncology and inflammation, and Public Health Solutions, which develops vaccines and therapeutics for military and civilian applications, including responses to ricin exposure, emerging infectious diseases, and viral diseases like Ebola, Marburg, and COVID-19. Soligenix highlights a robust pipeline with products in various stages of clinical trials, including promising candidates for conditions such as psoriasis and Behçet's disease. The presentation underlines collaborations with biotech firms, academia, and government agencies, along with non-dilutive government funding supporting vaccine development. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief on August 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Soligenix Inc. Unveils Corporate Presentation Focused on Advancements in Rare Disease Treatment and Robust Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoligenix Inc. Unveils Corporate Presentation Focused on Advancements in Rare Disease Treatment and Robust Pipeline\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-22 21:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Soligenix Inc. Unveils Corporate Presentation Focused on Advancements in Rare Disease Treatment and Robust Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SNGX\">Soligenix, Inc.</a>, a late-stage biopharmaceutical company, has released a corporate presentation detailing their focus on developing and commercializing products for the treatment of rare diseases with unmet medical needs. The company operates in two main segments: Specialized BioTherapeutics, which targets orphan diseases and unmet medical needs in oncology and inflammation, and Public Health Solutions, which develops vaccines and therapeutics for military and civilian applications, including responses to ricin exposure, emerging infectious diseases, and viral diseases like Ebola, Marburg, and COVID-19. Soligenix highlights a robust pipeline with products in various stages of clinical trials, including promising candidates for conditions such as psoriasis and Behçet's disease. The presentation underlines collaborations with biotech firms, academia, and government agencies, along with non-dilutive government funding supporting vaccine development. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief on August 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNGX","symbol_name":"Soligenix, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nNDL4bz7QT:1","article_id":"2561477461","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561477461","pubTimestamp":1755869535,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Soligenix, Inc., a late-stage biopharmaceutical company, has released a corporate presentation detailing their focus on developing and commercializing products for the treatment of rare diseases with unmet medical needs. The company operates in two main segments: Specialized BioTherapeutics, which targets orphan diseases and unmet medical needs in oncology and inflammation, and Public Health Solutions, which develops vaccines and therapeutics for military and civilian applications, including responses to ricin exposure, emerging infectious diseases, and viral diseases like Ebola, Marburg, and COVID-19. Soligenix highlights a robust pipeline with products in various stages of clinical trials, including promising candidates for conditions such as psoriasis and Behet's disease. The presentation underlines collaborations with biotech firms, academia, and government agencies, along with non-dilutive government funding supporting vaccine development. You can access the full presentation thro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNGX":"Soligenix, Inc.","BK4139":"生物科技"},"translate_title":"Soligenix Inc.发布企业演示文稿，重点介绍罕见病治疗的进步和强大的产品线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNGX":0.9},"content_text":"Soligenix Inc. Unveils Corporate Presentation Focused on Advancements in Rare Disease Treatment and Robust Pipeline\n    \n\nSoligenix, Inc., a late-stage biopharmaceutical company, has released a corporate presentation detailing their focus on developing and commercializing products for the treatment of rare diseases with unmet medical needs. The company operates in two main segments: Specialized BioTherapeutics, which targets orphan diseases and unmet medical needs in oncology and inflammation, and Public Health Solutions, which develops vaccines and therapeutics for military and civilian applications, including responses to ricin exposure, emerging infectious diseases, and viral diseases like Ebola, Marburg, and COVID-19. Soligenix highlights a robust pipeline with products in various stages of clinical trials, including promising candidates for conditions such as psoriasis and Behçet's disease. The presentation underlines collaborations with biotech firms, academia, and government agencies, along with non-dilutive government funding supporting vaccine development. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief on August 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}